Table 2.

Demographic and clinical characteristics of the patients submitted to vitrectomy

	Hereditary ATTRV30M – ‘Tafamidis Group’ (n=8 patients; n=10 vitreous*)	Hereditary ATTRV30M – ‘No Tafamidis Group’ (n=19 patients; n=23 vitreous#)
Patient Age (at vitrectomy) (mean ± s.d., max, min)	62.0 ± 8.7 years (max 72.1, min 47.2)	52.4 ± 9.1 years (max 72.4, min 39.4)
Gender	Female: n=7, Male: n=1	Female: n=9 Male: n=10
Age of disease onset (mean ± s.d., max, min)	53.6 ± 10.8 years (max 64.9, min 35.1)	37.2 ± 14.1 years (max 69.0, min 21.4)
Disease duration (mean ± s.d., max, min)	8.5 ± 2.9 years (max 14.5, min 4.5)	17.4 ± 5.3 years (max 26.2, min 8.5)
ATTRV30M Specific Treatment Description	Tafamidis 20mg per day orally	Liver Transplant: n=16 No Treatment: n=3⊥
Treatment duration (at vitrectomy) (mean ± s.d., max, min)	4.5 ± 2.3 years (max 8.0, min 1.7)	14.7 ± 5.2 years (max 21.9, min 4.3)

^*two patients (a woman and a man) underwent bilateral vitrectomy at different time points;

^#four patients (three men and one woman) underwent bilateral vitrectomy at different time points. For age, disease duration and treatment duration, each vitrectomy was considered separately (i.e., six patients were considered at two different time points). All remaining patients were considered at only one time point.

^⊥Three patients with no treatment because of the absence of peripheral nervous disease manifestations.